IQVIA Holdings Inc. (NYSE:IQV) Receives $249.05 Average PT from Brokerages

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one research firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $249.05.

IQV has been the topic of several analyst reports. Morgan Stanley upped their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Bank of America lowered their price target on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research report on Friday, December 13th. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target for the company. Finally, Barclays lowered their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd.

Remove Ads

IQVIA Price Performance

NYSE IQV traded down $2.85 on Monday, reaching $184.09. The company had a trading volume of 766,204 shares, compared to its average volume of 1,227,504. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $32.46 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm's 50 day moving average price is $195.71 and its 200 day moving average price is $209.36. IQVIA has a 12 month low of $179.28 and a 12 month high of $256.29.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA will post 10.84 earnings per share for the current year.

Institutional Trading of IQVIA

A number of hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in IQVIA by 83.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,861 shares of the medical research company's stock worth $1,938,000 after buying an additional 4,483 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ purchased a new position in IQVIA during the fourth quarter valued at $11,478,000. PKO Investment Management Joint Stock Co purchased a new position in IQVIA during the fourth quarter valued at $491,000. Mattson Financial Services LLC lifted its holdings in IQVIA by 20.9% during the fourth quarter. Mattson Financial Services LLC now owns 5,844 shares of the medical research company's stock valued at $1,148,000 after purchasing an additional 1,011 shares in the last quarter. Finally, Siemens Fonds Invest GmbH lifted its stake in shares of IQVIA by 973.2% in the fourth quarter. Siemens Fonds Invest GmbH now owns 21,345 shares of the medical research company's stock worth $4,195,000 after buying an additional 19,356 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.